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Introduction
The progressive enforcement of colorectal cancer (CRC)
screening programs and the improvement in endoscopic resec-
tion techniques are leading to a growing number of early CRCs
that are diagnosed and treated endoscopically and this number
is expected to increase [1, 2].
Endoscopic resection without subsequent surgery appears
to be a more conservative treatment, but the potential hazard
of lymph node metastasis may jeopardize its efficacy [3, 4].
Endoscopic and histological variables have been shown to be
reliable predictors of lymph node metastasis [5–9]; in particul-
ar, poor differentiation, tumor budding, lymphovascular inva-
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Background Implementation of colorectal cancer (CRC)
screening programs increases endoscopic resection of
polyps with early invasive CRC (pT1). Risk of lymph node
metastasis often leads to additional surgery, but despite
guidelines, correct management remains unclear. Our aim
was to assess the factors affecting the decision-making pro-
cess in endoscopically resected pT1-CRCs in an academic
center.
Methods We retrospectively reviewed patients undergo-
ing endoscopic resection of pT1 CRC from 2006 to 2016.
Clinical, endoscopic, surgical treatment, and follow-up
data were collected and analyzed. Lesions were categorized
according to endoscopic/histological risk-factors into low
and high risk groups. Comorbidities were classified accord-
ing to the Charlson comorbidity index (CCI). Surgical refer-
ral for each group was computed, and dissociation from
current European CRC screening guidelines recorded. Mul-
tivariate analysis for factors affecting the post-endoscopic
surgery referral was performed.
Results Seventy-two patients with endoscopically resect-
ed pT1-CRC were included. Overall, 20 (27.7%) and 52
(72.3%) were classified as low and high risk, respectively.
In the low risk group, 11 (55%) were referred to surgery, re-
presenting over-treatment compared with current guide-
lines. In the high risk group, nonsurgical endoscopic surveil-
lance was performed in 20 (38.5%) cases, representing
potential under-treatment. After a median follow-up of 30
(6–130) months, no patients developed tumor recurrence.
At multivariate analysis, age (OR 1.21, 95%CI 1.02–1.42;
P =0.02) and CCI (OR 1.67, 95%CI 1.12–3.14; P=0.04)
were independent predictors for subsequent surgery.
Conclusions A substantial rate of inappropriate post-
endoscopic treatment of pT1-CRC was observed when
compared with current guidelines. This was apparently
related to an overestimation of patient-related factors rath-
er than endoscopically or histologically related factors.
* Giulio Antonelli and Giammauro Berardi: These authors contributed equal-
ly.
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sion, deep submucosal invasion, and positive resection margins
have been associated with a higher risk of lymph node disease.
European CRC guidelines recommend additional surgical re-
section only for high risk lesions, while a conservative approach
appears more suitable for low risk lesions. However, such re-
commendations are based on weak evidence, leaving residual
uncertainty on the best treatment [10–12]. In addition, imple-
mentation of such guidelines in clinical practice is unclear, and
large variability may be expected. [5, 13].
The aim of this retrospective study was to assess the clinical
management of endoscopically resected pT1-CRC in an aca-




The hospital charts of patients who underwent a complete
endoscopic resection of a histologically proven pT1 lesion be-
tween June 2006 and December 2016 were reviewed, cross-re-
ferencing histological and endoscopic databases to marginalize
selection bias. In addition, we collected data on patients who in
the same time frame were sent from our endoscopy unit to up-
front surgery for a colonic lesion which resulted pT1 at patholo-
gy. Additional information on index and surveillance colonosco-
pies, histological data and possible surgical procedures, and
hospital stay were collected.
After the initial data collection, all patients were given an
identification number to guarantee anonymity and information
entered in a dedicated data base for statistical analysis. All pa-
tients gave informed consent for the use of clinical and labora-
tory data at the time of the first examination or procedure.
The study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki and was approved by the local in-
stitutional review board.
Center policy in the study period
Endoscopy – characterization and resection
In the study period, it was routine practice in our endoscopy
unit to use Paris criteria to morphologically classify the lesions
[14, 15]. Resection techniques were performed to ensure,
whenever possible, an en bloc, R0 resection. Polypectomy and
endoscopic mucosal resection (EMR) were available throughout
the entire study period, while endoscopic submucosal dissec-
tion (ESD) was started in 2013.
Polyps were sent to upfront surgery when morphological,
vascular or pit pattern characteristics suggested a high risk of
deeply invasive cancer.
Pathology staging
Tumor differentiation, presence of lymphovascular invasion,
depth of invasion (Haggitt and Kikuchi) [16, 17], and/or submu-
cosal infiltration in millimeters were regularly reported in the
study period, while the presence of budding was evaluated
starting from 2012.
It was general policy to classify lesions as low or high risk
polyps according to the presence of one or more of the above
mentioned pathology risk factors, and according to the resec-
tion modality (en bloc vs piece-meal) and presence of positive
resection margins (R1). For the purposes of this study, presence
of R1 at pathology was considered to be an exclusion criteria, as
potentially indicative of a cancer deeper than T1.
Multidisciplinary decision– surgery vs endoscopy
In the study period, patients with pT1-CRC were routinely re-
ferred to a multidisciplinary group involving gastroenterolo-
gists, oncologists, colorectal surgeons, radiologists, and pa-
thologists that would propose a treatment approach based on
pathological and clinical risk factors. The risk of surgery was
classified according to the presence of comorbidities using the
Charlson comorbidity index (CCI) [18]. When surgery was not
indicated, endoscopic surveillance was performed at 1 year,
and then after 3 and 5 years [19].
Study end points
To assess:
1. Management of endoscopically resected low risk pT1
(follow-up vs subsequent surgery).
2. Management of endoscopically resected high risk pT1
(subsequent surgery vs follow-up).
3. Main polyp- or patient-predictors of the endoscopic/surgery
approach.
4. Management of upfront surgically resected pT1.
In order to assess the appropriateness of our recommenda-
tions, we used the European CRC Screening Guidelines as refer-
ence standard [10].
Statistical analysis
Continuous data were reported as mean ± SD or as median
(range) and compared using the Student’s t test or Mann-Whit-
ney test as appropriate. Categorical variables were expressed as
number (percentage) and compared using the chi-squared test
with Fisher’s exact test using Yates correction as appropriate.
Overall survival (OS) was considered to be the time from pT1 le-
sion resection to death or last follow-up. Patients’ survival times
were evaluated using Kaplan-Meier curves and compared with
the log-rank test. A backward stepwise logistic regression mod-
el was performed to identify factors affecting the decision to
perform surgical resection. Statistical analysis was performed
using IBM SPSS Statistics for Mackintosh, Version 20.0 (IBM
Corp., Armonk, NY).
Results
In the study period, 93 pT1-CRC were identified, corresponding
to 1.4% (93/6440) of all the endoscopic resections performed
in the study period. In addition, 24 colonic lesions that were
sent from our endoscopy unit to upfront surgery subsequently
resulted as pT1 at pathology.
For the purpose of this study, 21 patients were excluded (5
for neuroendocrine tumors, 3 for R1, 3 for previous or synchro-















































nous advanced CRC, 10 lost to follow-up). Finally, 96 patients
were included in the final analysis, 72 (75%) with endoscopic
resection and 24 (25%) patients sent to upfront surgery. De-
mographics and clinical characteristics are shown in ▶Table1,
while a patient management flow chart is shown in ▶Fig. 1.
Endoscopically resected low risk polyps
Overall, 20/72 (27.8%) patients presented with a low risk pT1-
CRC after endoscopic resection. Of these, 11/20 (55%, 95%CI:
0.34–0.74) were referred to surgery and 9/20 (45%, 95%CI:
0.25–0.65) to endoscopic follow-up. This corresponds to an in-
appropriate management of 55%, compared with the reference
standard. In particular, 9/11 operated patients had a peduncu-
lated polyp while two were Laterally Spreading Tumors. Eight
patients underwent a videolaparoscopic emicolectomy, while
three underwent open emicolectomy. When surgical risk was
considered, 6/11 patients were found to have an increased sur-
gical risk (CCI≥3). As for the 9/20 patients referred to endo-
scopic surveillance, 8/9 (89%) had a pedunculated polyp, while
the surgical risk was low in 4/9 (44%) patients.
Endoscopically resected high risk polyps
Overall, 52/72 patients (72.2%) presented with high risk pT1-
CRC after endoscopic resection. The presence of histologic risk
factors is detailed in ▶Table 2. In detail, 20/52 (38.5%, 95%CI:
0.26–0.52) were followed up endoscopically, while 32/52
(61.5%, 95%CI: 0.48–0.73) underwent surgical intervention.
This corresponds to an inappropriate management of 38.5% of
patients according to the reference standard. Among those fol-
lowed up at endoscopy, 16/20 (80%) patients were found to
have an increased surgical risk (≥3 CCI). Of the remaining four
patients, two had a very low rectal localization. Among patients
referred to surgery, 5/32 had a CCI≥3.
One patient from the high risk group who underwent subse-
quent surgery had lymph node metastasis (LNM) in 1 out of 20
lymph nodes dissected (N1). The percentage of LNM in endo-
scopically resected pT1-CRC sent to subsequent surgery was
2.3%.
Predictors of clinical management of endoscopically
resected pT1-CRC (post polypectomy surgery vs
follow-up) and survival
When considering cumulatively the low and high risk groups,
after endoscopic resection, 43/72 (59.7%) were referred for
subsequent surgical resection, while 29/72 (40.3%) were fol-
lowed up with only endoscopic surveillance. The main demo-
graphic and clinical characteristics of the two groups are shown
in ▶Table 3. In detail, the median age in the endoscopy group
appeared to be significantly higher than that of the surgery
group (74, range: 43–94 vs 67, range 36–83; P=0.008), and a
lower number of patients surgically treated appeared to have
comorbidities (mean CCI value: 2.3±1.3 vs 3.1 ±1.3 P=0.01).






















▶ Fig. 1 Patient management flow chart. White squares show pa-
tients managed according to guidelines. Black squares show pa-
tients managed outside guidelines. *Exclusion criteria listed in
Methods section.
▶ Table 1 Patient demographics and endoscopic characteristics.
Gender (F/M) 46/50
Age, median (range), years 70 (36–94)
Comorbidities (CCI1), mean ± SD 2.6 (± 1.28)
Tumor site
▪ Right colon 16 (17%)
▪ Left colon 17 (18%)
▪ Sigma 30 (31%)
▪ Rectum 33 (34%)
Tumor size, mean ± SD, mm 20.4 (± 1.9)
Paris classification
▪ 0-Ip 41 (42%)
▪ 0-Is 32 (34%)
▪ 0-Isp 5 (5%)
▪ 0-IIa 2 (2%)
▪ 0-IIb 5 (5%)
▪ 0-IIc 1 (1%)
▪ LST-G 7 (8%)
▪ LST-NG 3 (3%)
Resection
▪ Upfront surgery 24 (25%)
▪ Endoscopy and surgery 43 (45%)
▪ Endoscopy 29 (30%)
Lymph node metastasis 4 (4.1%)
1 CCI =Charlson comorbidity Index.
















































No additional differences were found concerning endoscopic
and histological characteristics (▶Table 4), with the only ex-
ception being Haggitt 1 lesions, which were more prevalent in
the group on endoscopic surveillance (24.1% vs 2.3%; P=
0.003). After a median follow-up of 30 (2–130) months, the
1-, 3-, and 5-year overall survival of patients undergoing sur-
gery was 100%, 96%, and 89%, respectively while it was 96%,
90%, and 90% for patients undergoing endoscopic surveillance
(P=0.47; ▶Fig. 2). No patients developed cancer recurrences.
During follow-up colonoscopies, 17 polyps in 13 (18%) patients
were endoscopically removed, all adenomas with low or high
grade dysplasia.
The logistic regression model showed that only age (OR
1.21, 95%CI 1.02–1.42; P=0.02) and comorbidities (CCI) (OR
1.67, 95%CI 1.12–3.14; P=0.04) were independently associat-
ed with post-endoscopic surgery (▶Table5).
Upfront surgery group
Among the 24 patients who were sent to upfront surgery for
pT1-CRC, 7/24 (29%) harbored low risk polyps, while 17/24
(71%) polyps had at least one histological risk factor for LNM.
Indeed, 3/24 (12.5%) had at least one pathologically proven
LNM, all from high risk polyps. This highlights potential mis-
management in 29% of patients who were sent to upfront sur-
gery with a low risk lesion. Four low risk lesions had endoscopic
risk factors for deep submucosal invasion (3 depression, 1 non-
lifting sign), while 3 lesions were evaluated as non endoscopi-
cally approachable for size.
▶ Table 2 Histopathological characteristics and risk factors.
Grading G1/G2/G3 21/53/22
Haggitt
▪ 1 8 (8%)
▪ 2 15 (15%)
▪ 3 7 (7%)
▪ 4 11 (11%)
Kikuchi score
▪ Sm1 14 (14%)
▪ Sm2 11 (11%)
▪ Sm3 7 (7%)
Submucosal infiltration, mean ± SD, mm 4.6 (± 5.4)
Lymphovascular invasion 24 (23%)
Budding
▪ 0–4 Buds 11 (11%)
▪ 5–9 Buds 6 (6%)
▶ Table 3 Demographics and endoscopic characteristics of patients with endoscopically resected pT1 CRCs.
Endoscopy+ surgery Endoscopy (n =29) P value
Gender (F/M) 20/23 16/13 0.31
Age 67 (36–83) 74 (43–94) 0.008
Comorbidities (Charlson Comorbidity Index), mean ± SD 2.3 ±1.3 3.1 ± 1.3 0.01
Tumor site
▪ Right colon 5 (11.6%) 5 (17.2%) 0.5
▪ Left colon 4 (9.3%) 1 (3.4 %)
▪ Sigma 21 (48.8%) 11 (37.9%)
▪ Rectum 13 (30.2%) 12 (41.3%)
Tumor size, mean ± SD, mm 17.2 ±9 17.5 ±8 0.89
Paris classification
▪ 0-Ip 22 (51.1%) 14 (48.2%) 0.39
▪ 0-Is 9 (20.9%) 10 (34.4%)
▪ 0-Isp 4 (9.3%) 1 (3.4 %)
▪ 0-IIa 1 (2.3%) 0 (0%)
▪ 0-IIb 4 (9.3%) 1 (3.4 %)
▪ 0-IIc 0 (0%) 1 (3.4 %)
▪ LST-G 1 (2.3%) 2 (6.8 %)
▪ LST-NG 2 (4.6%) 0 (0%)
















































According to our data, an unexpected high rate of discordance
exists between real-life clinical management and current
guidelines when dealing with endoscopically resected pT1-
CRC. In particular, a high rate of over-treatment of low risk le-
sions was reported, with an apparently unnecessary use of sur-
gical resources. On the other hand, more than 1 in every 3 pa-
tients with high risk lesions were not operated on, potentially
remaining at risk of tumor progression. In addition, we showed
that clinically related factors, such as age and comorbidities,
played a dominant role in the decision-making process, while
the role of endoscopic and histological factors appeared to be
somewhat downgraded.
Our results are relevant for the following considerations.
First, most of the low risk lesions sent to surgery disappointing-
ly presented with a pedunculated morphology. Thus, indication
to surgery was apparently related to a clinical choice, as the risk
of incomplete resection is to be ruled out. In this regard, it must
be admitted that the evidence in favor of a conservative ap-
proach for low risk lesions is weak, mostly based on retrospec-
tive historical series.
Second, there is compelling evidence that such patients
never have a 0% risk of LNM, and inconstant risk ratios have
been described [5, 20]. Thus, it may be suggested that when
comparing such risk with the mortality risk from CRC surgery
in patients at low risk of surgery, the surgical choice still ap-
peared attractive: young and healthy patients were more likely
referred to surgery considering long life expectation and low
procedure-related morbidity; conversely, patients with high
risk pT1 lesions were more likely followed up endoscopically
when the risk for morbidity and mortality of the surgical proce-
dure was high.
Third, oncological benefit of post-endoscopic surgical refer-
ral was questionable in both low and high risk lesions. Surgical
approach does not seem to benefit the outcome, since survival
in both groups was comparable, and no patient developed re-
▶ Table 4 Histopathological characteristics of endoscopically resected pT1 CRCs.
Endoscopy+ surgery (n =43) Endoscopy (n=29) P value
Grading G1/G2/G3 7/24/12 6/18/5 0.56
Haggitt
▪ 1 1 (2.3%) 7 (24.1%) 0.003
▪ 2 12 (27.9%) 3 (10.3%)
▪ 3 5 (11.6%) 0 (0%)
▪ 4 16 (37.2%) 15 (51.7%)
Kikuchi score
▪ Sm1 7 (16.2%) 8 (27.5%) 0.7
▪ Sm2 5 (1.6%) 4 (13.7%)
▪ Sm3 4 (9.3%) 2 (6.8%)
Submucosal infiltration, mm 3.3 ±2 2.5 ±3 0.28
Lymphovascular invasion 9 (20.9%) 5 (17.2%) 0.47
Budding
▪ 0–4 Buds 5 (11.6%) 6 (20.6%) 0.32
▪ 5–9 Buds 2 (4.6%) 0 (0%)



























▶ Fig. 2 Overall survival of patients.
















































currence. This is crucial in the clinical decision-making process,
since it is well known that surgical resection harbors higher
risks [21].
The lack of benefit of surgical resection could be ascribable
to the small sample size in our cohort; however, a recent multi-
center Asian retrospective study on high risk pT1-CRCs with
▶ Table 5 Predictive factors for surgical approach after endoscopic resection.
Univariate analysis Multivariate analysis
OR (95%CI) P value OR (95%CI) P value
Female sex 0.38 (0.03 –3.77) 0.41
Age 1.24 (1.05 –1.46) 0.009 1.21 (1.02 –1.42) 0.02
Comorbidities 2.21 (1.01 –5.27) 0.05 1.67 (1.12 –3.14) 0.04
Tumor site
▪ Right colon 1 0.70
▪ Left colon 0.63 (0.05 –7.07)
▪ Sigma 0.03 (0.00 –3.10)
▪ Rectum 0.23 (0.02 –2.61)
Tumor size 1.02 (0.93 –1.11) 0.67
Parigi classification
▪ 0-Ip 1 0.99
▪ 0-Is 6.26 (0.00 –9.75)
▪ 0-Isp 0.97 (0.00 –1.23)
▪ 0-IIa 0.92 (0.00 –9.70)
▪ 0-IIb 0.98 (0.00 –1.63)
▪ 0-IIc 1.26 (0.00 –1.28)
▪ LST-G 1.06 (0.00 –6.71)
▪ LST-NG 1.09 (0.00 –6.26)
Grading
▪ G1 1 0.20
▪ G2 1.02 (0.32 –1.42)
▪ G3 8.01 (0.00 –11.4)
Haggitt
▪ 1 1 0.79
▪ 2 1.03 (0.00 –6.8)
▪ 3 1.05 (0.03 –8.8)
▪ 4 6.06 (0.00 –11.5)
Kikuchi score
▪ Sm1 1 0.93
▪ Sm2 1.47 (0.04 –3.43)
▪ Sm3 2.22 (0.91 –5.16)
Submucosal infiltration, mm 0.95 (0.68 –1.34) 0.79
Lymphovascular invasion 0.03 (0.00 –1.78) 0.53
Budding 5–9 buds 2.49 (0.88 –3.28) 0.07
En bloc resection 1.28 (0.35 –4.68) 0.70















































long-term follow-up also found no survival benefit in patients
treated with additional surgery [22]. Furthermore, it could be
a clue to the great heterogeneity of histological risk factors
and the lack of standardization in reporting them, as suggested
previously [5]. Indeed, most available studies are based on
Asian data, where histological workout is thorough and yields
more certain results. Thus, to safely identify patients who can
be spared from surgical intervention, it is necessary to establish
cutoffs, risk stratification models and clear definitions for every
risk factor, increasing reproducibility.
It is possible that, in the near future, a refined risk stratifica-
tion capability will expand indications for endoscopic resection
and surveillance of pT1-CRCs. Until then, our data indicate that
the final decision-making is still predominantly driven by clini-
cal factors, as well as patient preferences. Since real life man-
agement of patients largely differs from available guidelines, it
is possible that these do not yet fully address clinical needs. In-
deed, it is conceivable that the mismanagement we highlighted
may be ascribable to the lack of high quality evidence to guide
informed choices.
To the best of our knowledge, this is the first recent Italian
study that investigates pT1-CRC management in a real life con-
secutive cohort of unselected patients from a single center. The
inclusion of patients outside the age range of screening pro-
grams could be the main cause of discrepancy between our
study and that of Fasoli et al., who found no age difference be-
tween the different treatment approaches [23]. We believe
however that inclusion of these patients is of great importance
when investigating a real life approach, since it is in the treat-
ment of the very young or the very old that the most challen-
ging decisions lie.
Our study also highlighted a quota of patients with low risk
pT1 that were sent to upfront surgery, potentially exposing
them to unnecessary risks. This was mainly driven by endo-
scopic characteristics that suggested increased risk of invasive
cancer or by perceived technical difficulties. Indeed, all these
patients were sent to surgery before 2010. We can assume
that this fraction of patients is decreasing along with the im-
provement in endoscopic diagnosis and resection techniques.
The present study has some limitations. First, having the ob-
jective of analyzing the decision-making process, it has a retro-
spective design based on clinical and procedural records, and as
such, may be affected by selection bias, which was margina-
lized by cross-referencing histological and endoscopic records.
Second, the sample size is not sufficient to guarantee a satisfac-
tory statistical power useful to discern small differences be-
tween groups. Indeed, our comprehensive LNM rate was 4.1%,
lower than mean rates reported in the literature. However, ex-
pressing LNM rate was not among the main purposes of this
study.
Conclusion
A substantial rate of inappropriate post-endoscopic treatment
of pT1-CRC was observed, when compared with current guide-
lines. This was apparently related to an overestimation of pa-
tient-related factors rather than endoscopically or histological-
ly related factors. A large multicenter study would be of great
interest to further analyze clinical management of pT1-CRC
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